Qureator is proud to announce a new partnership with the Physicians Committee for Responsible Medicine (PCRM) to host an exclusive in-person workshop during the Society of Toxicology (SOT) 2026 Annual Meeting in San Diego. This collaboration reflects our shared commitment to advancing human-relevant, non-animal approaches in next-generation toxicology and risk assessment.
Qureator is proud to unveil the future of drug discovery at BIO 2025.
Qureator is proud to announce its participation at ARVO 2025, unveiling its pioneering iPSC-derived 3D outer Blood-Retinal Barrier (oBRB) model. Using Curiochips™ technology, the model faithfully replicates key features of both…
Qureator invites you to unlock your drug’s potential at AACR 2025, booth #5016! Explore how our cutting-edge vascularized 3D tumor models enable advanced evaluation of immuno-oncology drug efficacy and mechanism of action (MOA).
Qureator fills this critical need. By combining physiologically relevant 3D disease models with scalable data generation, the platform bridges the divide between computational discovery and translational impact.
Qureator is excited to announce its upcoming presentation at the WuXi AppTec Japan webinar on March 12, 2025.
Qureator extends a heartfelt thank you to CSEM for hosting an outstanding event at the Next-Generation Organ-on-Chips & Organoids Workshop held on February 13th in Basel.
Qureator is pleased to announce that CEO Dr. Kyu Baek will present the company’s newest innovation—the Vascularized Tumor Immune Microenvironment (vTIME) platform—at the CSEM Next-Gen Organ-on-Chips & Organoids Workshop on February 14th in Basel.